Teja Sai Kiran Polisetty, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Shoulder Joint | 13 | 2024 | 740 | 2.890 |
Why?
|
| Osteoarthritis | 5 | 2023 | 1051 | 1.610 |
Why?
|
| Arthroplasty, Replacement, Knee | 5 | 2023 | 1378 | 0.740 |
Why?
|
| Arthroplasty, Replacement, Hip | 5 | 2023 | 1414 | 0.700 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2022 | 374 | 0.600 |
Why?
|
| Orthopedics | 2 | 2022 | 901 | 0.550 |
Why?
|
| Range of Motion, Articular | 8 | 2023 | 1593 | 0.530 |
Why?
|
| Fractures, Stress | 3 | 2023 | 202 | 0.480 |
Why?
|
| Fractures, Bone | 3 | 2024 | 2041 | 0.450 |
Why?
|
| Acromion | 4 | 2024 | 32 | 0.350 |
Why?
|
| Insurance | 2 | 2021 | 115 | 0.320 |
Why?
|
| Scapula | 2 | 2024 | 175 | 0.250 |
Why?
|
| Retrospective Studies | 18 | 2023 | 81565 | 0.230 |
Why?
|
| Arthroplasty | 2 | 2023 | 305 | 0.210 |
Why?
|
| Shoulder Dislocation | 1 | 2024 | 129 | 0.210 |
Why?
|
| Length of Stay | 5 | 2022 | 6490 | 0.200 |
Why?
|
| Synovitis, Pigmented Villonodular | 1 | 2020 | 31 | 0.180 |
Why?
|
| Treatment Outcome | 11 | 2023 | 65219 | 0.170 |
Why?
|
| Osteolysis | 1 | 2022 | 271 | 0.170 |
Why?
|
| Arthritis, Infectious | 1 | 2023 | 347 | 0.160 |
Why?
|
| Shoulder Pain | 1 | 2020 | 152 | 0.160 |
Why?
|
| Ectropion | 1 | 2018 | 27 | 0.150 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2021 | 340 | 0.150 |
Why?
|
| Rotator Cuff | 1 | 2021 | 348 | 0.150 |
Why?
|
| Prosthesis-Related Infections | 1 | 2023 | 497 | 0.140 |
Why?
|
| Arthritis | 1 | 2023 | 676 | 0.140 |
Why?
|
| Artificial Intelligence | 2 | 2022 | 2662 | 0.140 |
Why?
|
| Arthroscopy | 1 | 2024 | 969 | 0.140 |
Why?
|
| Joint Instability | 1 | 2024 | 802 | 0.130 |
Why?
|
| Eyelids | 1 | 2018 | 278 | 0.130 |
Why?
|
| Sarcopenia | 1 | 2020 | 378 | 0.120 |
Why?
|
| Postoperative Complications | 6 | 2024 | 15808 | 0.120 |
Why?
|
| Aged | 10 | 2024 | 171219 | 0.110 |
Why?
|
| Reoperation | 1 | 2024 | 4309 | 0.110 |
Why?
|
| Outpatients | 1 | 2020 | 1596 | 0.100 |
Why?
|
| Humans | 24 | 2024 | 766117 | 0.100 |
Why?
|
| Patient Readmission | 2 | 2020 | 3283 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 5531 | 0.070 |
Why?
|
| Patient Discharge | 1 | 2020 | 3465 | 0.070 |
Why?
|
| Risk Factors | 6 | 2023 | 74857 | 0.070 |
Why?
|
| Medicare | 1 | 2022 | 6820 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 59515 | 0.050 |
Why?
|
| Propionibacterium acnes | 1 | 2021 | 59 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2023 | 41684 | 0.040 |
Why?
|
| Dermis | 1 | 2021 | 204 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2020 | 24276 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2021 | 740 | 0.040 |
Why?
|
| United States | 2 | 2022 | 72920 | 0.040 |
Why?
|
| Female | 7 | 2024 | 396233 | 0.030 |
Why?
|
| Male | 6 | 2024 | 363935 | 0.030 |
Why?
|
| Reaction Time | 1 | 2018 | 2086 | 0.020 |
Why?
|
| Recurrence | 1 | 2024 | 8494 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2024 | 4044 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2024 | 8724 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 39243 | 0.020 |
Why?
|
| Skin | 1 | 2021 | 4482 | 0.020 |
Why?
|
| Middle Aged | 3 | 2024 | 223083 | 0.010 |
Why?
|
| Incidence | 1 | 2021 | 21513 | 0.010 |
Why?
|
| Quality of Life | 1 | 2023 | 13468 | 0.010 |
Why?
|
| Algorithms | 1 | 2022 | 14066 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 20700 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2021 | 54812 | 0.010 |
Why?
|